Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC008512 | Panoply™ Human LACTB Knockdown Stable Cell Line | Inquiry |
| CSC-SC008512 | Panoply™ Human LACTB Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD08984Z | Human LACTB adenoviral particles | Inquiry |
| LV16713L | human LACTB (NM_171846) lentivirus particles | Inquiry |
| LV16714L | human LACTB (NM_032857) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH328103 | shRNA set against Human LACTB (NM_032857.3) | Inquiry |
| SHH140905 | shRNA set against Mouse Lactb(NM_030717.1) | Inquiry |
| SHH328107 | shRNA set against Mouse LACTB (NM_030717.1) | Inquiry |
| SHH328111 | shRNA set against Rat LACTB (NM_001106833.1) | Inquiry |
| SHW001202 | shRNA set against Chicken LACTB (NM_001030546) | Inquiry |
| SHW008659 | shRNA set against Danio rerio LACTB (NM_001020593) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR006561 | Rat Lactb cDNA Clone(NM_001106833.1) | Inquiry |
| MiUTR1M-06503 | LACTB miRNA 3'UTR clone | Inquiry |
| MiUTR3H-10001 | LACTB miRNA 3'UTR clone | Inquiry |
| MiUTR3H-10002 | LACTB miRNA 3'UTR clone | Inquiry |
| CDCB162677 | Chicken LACTB ORF Clone (NM_001030546) | Inquiry |
| CDCB170134 | Danio rerio LACTB ORF Clone (NM_001020593) | Inquiry |
| CDCB186618 | Rabbit LACTB ORF clone (XM_002718193.2) | Inquiry |
| CDCL126015 | Mouse Lactb ORF clone (NM_030717.1) | Inquiry |
| CDCR007628 | Human LACTB ORF clone(NM_032857.3) | Inquiry |
| CDCR373571 | Rat Lactb ORF Clone(NM_001106833.1) | Inquiry |
Recent Progress
LACTB gene encodes the 54 kDa protein LACTB, which shares significant sequence similarity to serine proteases of the penicillin binding protein and beta-lactamase superfamily existing in bacteria. LACTB is associated with the regulation of the metabolic circuitry. This protein is widely studies due to its relationship with diseases. Researchers have already discovered a causal association between LACTB and obesity. LACTB also play a role in tumor suppressing by modulating lipid metabolism in breast cancer. This role of LACTB also believed to be functioning through its effect on mitochondrial phospholipid metabolism and modulation of cell differentiation state. It has been suggested LACTB could promote intra-mitochondrial membrane organization, regulate electron transport chain complex I, and control cellular metabolism(Fig. 1).
Fig. 1. Three-dimensional model of LACTB shows the position of the predicted
coiled-coil segment (yellow arrows), and the side chains of the catalytic site residues (yellow). (Z Polianskyte et al, 2009)
Through gene expression profiles, researchers revealed that, compared with muscle progenitor cells, LACTB was overexpressed in differentiated, post-mitotic muscle cells. After the study of 18 breast cancer cell lines, researchers proposed that LACTB overexpression decreased proliferation in breast cancer cell lines and LACTB induction invoked tumor regression in vivo. More specifically, LACTB expression promoted epithelial differentiation of breast cancer cells and reduced expression of the mitochondrial phospholipids lysophosphatidylethanolamines (LPE) and phosphatidylethanolamines (PE). Further findings also suggested that LACTB controls proliferation and differentiation, through regulation of mitochondrial phospholipids.
Another group of researchers was able to propose that the LACTB potently inhibits the proliferation of breast cancer cells, with in vitro and in vivo studies in mice and humans. The specific mechanism involves alteration of mitochondrial lipid metabolism and differentiation of breast cancer cells. Researchers believed that this mechanism is achieved, to some extent, through reduction of the levels of mitochondrial phosphatidylserine decarboxylase.
In order to identify the upregulated genes in differentiated post-mitotic human and murine muscle cells as compared to their actively cycling progenitors, researchers conducted a microarray analysis. LACTB overexpression had the biggest influence on decreasing the rate of proliferation of breast cancer cell lines, but only had only minimal effect on the proliferation of non-tumorigenic cell lines. Moreover, LACTB were downregulated in over a third of breast cancer tissues out of 714 clinical samples. There has been complete disappearance of the tumour mass, suggesting that exogenous expression of LACTB in already-formed tumors caused tumor regression. These findings taken together further confirmed that the protease LACTB is a novel tumour suppressor, functioning through the control of mitochondrial lipid metabolism.
Moreover, through the mouse studies in vitro, researchers were able to suggest that a fluorescent substrate of the Mycobacterium tuberculosis enzyme LACTB could be a useful TB(tuberculosis) diagnostic marker. In the macrophages of cultured M. tuberculosis–infected mouse, the fluorescent substrate produced a signal that could be associated with bacterial number, compared with uninfected cells. Still in the cultured M. tuberculosis–infected mouse, compared with no treatment, a TB therapeutic resulted in a decreased fluorescence signal. Based on the findings above, further steps including further development of in vitro assays using the fluorescent substrate may be carried out. It has been reported that at least eight companies have LACTB inhibitors in development stages, ranging from preclinical to marketed for a variety of bacterial infections.
References: